Denmark Team Develops mRNA Vaccine for Food Allergies
Researchers at the Technical University of Denmark report protective antibody responses against several related food allergens in mice.
Updated on Nov. 20, 2026 in Nutrition

Live Poll
Would you accept a vaccine that protects against several food allergies at once?
The Technical University of Denmark has developed an experimental mRNA vaccine targeting multiple food allergens, using the same messenger RNA technology as COVID-19 vaccines. In a study published in Nature Communications in February 2026, the vaccine stimulated production of protective antibodies against several related allergens in mice.
Why it matters
More than 220 million people worldwide suffer from food allergies, and current treatments require exposure to increasing amounts of the allergen over several years. The vaccine's approach offers a different route, though the mouse results did not provide complete protection against anaphylaxis at the tested doses.
The evidence comes from mouse studies published in Nature Communications, with antibodies from vaccinated mice also blocking reactions in human samples in laboratory tests. Healthy mice received three doses three weeks apart, but the optimal dosage and schedule remain undetermined and complete anaphylaxis protection was not observed.
The players
Technical University of Denmark
A Danish public research university based in Kongens Lyngby that conducts engineering and natural science research, including the development of this experimental allergy vaccine.
Nature Communications
A peer-reviewed open-access scientific journal published by Nature Portfolio that features multidisciplinary research and published the mouse study.
The details
The vaccine contains a synthetic allergen designed to target several related allergens found in peaches and certain nuts, and it instructs the body to produce antibodies that block allergens before they trigger a reaction. Researchers are refining the lipid particles that carry the immune-activating components and plan larger mouse studies before moving toward human trials.
Timeline
February 2026: Nature Communications publishes the mouse vaccine study.
Researchers plan additional mouse studies with larger groups to determine optimal dosage and vaccination schedule.
Roadmap
The study applies the messenger RNA platform used in COVID-19 vaccines to food allergies, extending a technology previously proven against infectious disease. Current allergy treatments depend on years of gradually increasing allergen exposure, making a vaccine-based alternative a notable change in approach.
If successful in humans, a vaccine could reduce reliance on years of gradual allergen exposure, which current treatments require. The approach is still at the mouse-study stage, so no changes to daily allergy management are available yet.
The takeaway
Food allergy sufferers should continue following existing medical guidance, since this vaccine remains at an early research stage with human trials not yet begun. Anyone managing a food allergy should consult an allergist about current treatment options.
Further reading
Explore more on food allergies and diet in our Nutrition section.
Source note: This article includes information reported by Newsweek.
Live Poll
Would you accept a vaccine that protects against several food allergies at once?



